Shell Asset Management Co. Sells 18,992 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Shell Asset Management Co. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,635 shares of the biopharmaceutical company's stock after selling 18,992 shares during the period. Shell Asset Management Co.'s holdings in Gilead Sciences were worth $6,155,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Redwood Financial Network Corp increased its holdings in Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares in the last quarter. Nicolet Advisory Services LLC boosted its position in Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after buying an additional 100 shares during the last quarter. Southland Equity Partners LLC boosted its position in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 110 shares during the last quarter. Berkshire Bank boosted its position in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares during the last quarter. Finally, CFO4Life Group LLC boosted its position in Gilead Sciences by 2.7% in the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after buying an additional 112 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 25,429 shares of company stock worth $2,894,445. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on GILD shares. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Up 3.6%

Shares of NASDAQ:GILD traded up $3.66 during midday trading on Monday, reaching $106.16. The company had a trading volume of 8,559,921 shares, compared to its average volume of 7,680,960. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business's 50 day moving average price is $105.75 and its 200 day moving average price is $99.84. The stock has a market cap of $132.06 billion, a PE ratio of 286.92, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.32) earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.